冠状动脉CT血管造影检出的非阻塞性冠状动脉疾病改善风险分层与他汀治疗分配
本研究通过Meta分析确定非阻塞性冠状动脉疾病对动脉粥样硬化性心血管疾病事件的汇总风险比为3.2(95%CI 1.5-6.7),并将其纳入ACC/AHA汇总队列方程,发现可使14%的患者他汀治疗资格被重新分类,从而改善风险分层并实现个体化他汀分配。
要点
- 冠状动脉CT血管造影检出的非阻塞性冠状动脉疾病与动脉粥样硬化性心血管疾病事件风险升高相关,汇总风险比为3.2(95%CI 1.5-6.7)。
- 将非阻塞性冠状动脉疾病信息纳入汇总队列方程后,14%的患者他汀治疗资格被重新分类。
- 非阻塞性冠状动脉疾病的存在与否可跨性别和种族群体个体化调整他汀治疗分配。
核心结论
- 冠状动脉CT血管造影检测非阻塞性冠状动脉疾病可改善风险分层,并允许跨性别和种族群体个体化、更适当地分配他汀治疗。
研究设计与样本
- 本研究从已发表研究中确定非阻塞性冠状动脉疾病对动脉粥样硬化性心血管疾病事件的汇总风险比,并将其纳入ACC/AHA汇总队列方程;纳入2项研究共2295名受试者(66%男性,非阻塞性冠状动脉疾病患病率47%,中位随访49个月,67例动脉粥样硬化性心血管疾病事件)。
诊断标准与关键数值
- 非阻塞性冠状动脉疾病对动脉粥样硬化性心血管疾病事件的风险比为3.2(95%CI 1.5-6.7)。
- 纳入非阻塞性冠状动脉疾病信息后,向符合他汀治疗资格重新分类的原始动脉粥样硬化性心血管疾病评分阈值:非洲裔美国女性3.0%或更高、非洲裔美国男性5.9%或更高、白人女性4.4%或更高、白人男性4.6%或更高。
- 无非阻塞性冠状动脉疾病时,向不符合他汀治疗资格重新分类的原始动脉粥样硬化性心血管疾病评分阈值:非洲裔美国女性10.0%或更低、非洲裔美国男性17.9%或更低、白人女性13.7%或更低、白人男性14.3%或更低。
- 重新分类在14%的患者中观察到。
临床应用与阅片要点
- 作者认为,通过冠状动脉CT血管造影检测非阻塞性冠状动脉疾病可改善风险分层,并允许跨性别和种族群体个体化、更适当地分配他汀治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study sought to determine prognostic value of nonobstructive coronary artery disease (CAD) for atherosclerotic cardiovascular disease (ASCVD) events and to determine whether incorporation of this information into the pooled cohort equation reclassifies recommendations for statin therapy as defined by the 2013 guidelines for cholesterol management of the American College of Cardiology and American Heart Association (ACC/AHA).
BACKGROUND: Detection of nonobstructive CAD by coronary computed tomography angiography may improve risk stratification and permit individualized and more appropriate allocation of statin therapy.
METHODS: This study determined the pooled hazard ratio of nonobstructive CAD for ASCVD events from published studies and incorporated this information into the ACC/AHA pooled cohort equation. The study calculated revised sex- and ethnicity-based 10-year ASCVD risk and determined boundaries corresponding to the original 7.5% risk for ASCVD events. It also assessed reclassification for statin eligibility by incorporating the results from meta-analysis to individual patients from a separate cohort.
RESULTS: This study included 2 studies (2,295 subjects; 66% male; prevalence of nonobstructive CAD, 47%; median follow-up, 49 months; 67 ASCVD events). The hazard ratio of nonobstructive CAD for ASCVD events was 3.2 (95% confidence interval: 1.5 to 6.7). Incorporation of this information into the pooled cohort equation resulted in reclassification toward statin eligibility in individuals with nonobstructive CAD, with an original ASCVD score of 3.0% and 5.9% or higher in African-American women and men and a score of 4.4% and 4.6% or higher in Caucasian women and men, respectively. The absence of nonobstructive CAD resulted in reclassification toward statin ineligibility if the original ASCVD score was as 10.0% and 17.9% or lower in African-American women and men and 13.7% and 14.3% or lower in Caucasian women and men, respectively. Reclassification is observed in 14% of patients.
CONCLUSIONS: Detection of nonobstructive CAD by coronary computed tomography angiography improves risk stratification and permits individualized and more appropriate allocation of statin therapy across sex and ethnicity groups.
引用
- Emami H, Takx RAP, Mayrhofer T, et al. Nonobstructive Coronary Artery Disease by Coronary CT Angiography Improves Risk Stratification and Allocation of Statin Therapy. JACC Cardiovasc Imaging. 2017. PMID: 28330658. doi:10.1016/j.jcmg.2016.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。